UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Oragenics, Inc.

--------------------------------------------------------------------------------

(Name of Issuer)

Common Stock, $.001 par value per share

--------------------------------------------------------------------------------

(Title of Class of Securities)

684023 10 4

--------------------------------------------------------------------------------

(CUSIP Number)

Daniel H. Luciano, Esq.

242A West Valley Brook Road

Califon, New Jersey 07830

(908) 832-5546

--------------------------------------------------------------------------------

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

August 8, 2007

--------------------------------------------------------------------------------

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the

following box. |_|

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 684023 10 4

--------------------------------------------------------------------------------

1. Names of Reporting Persons. I.R.S. Identification Nos. of above

persons (entities only)

George T. Hawes

--------------------------------------------------------------------------------

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ................................................................[ ]

(b) ................................................................[ ]

--------------------------------------------------------------------------------

3. SEC Use Only .......................................................

--------------------------------------------------------------------------------

4. Source of Funds (See Instructions) PF

--------------------------------------------------------------------------------

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to

Items 2(d) or 2(e) .................................................

--------------------------------------------------------------------------------

6. Citizenship or Place of Organization U.S.A

--------------------------------------------------------------------------------

7. Sole Voting Power 6,440,767

------------------------------------------------------------------

Number of

Shares 8. Shared Voting Power ......................................

Beneficially

Owned by ------------------------------------------------------------------

Each

Reporting 9. Sole Dispositive Power 6,440,767

Person With

------------------------------------------------------------------

10. Shared Dispositive Power .................................

--------------------------------------------------------------------------------

11. Aggregate Amount Beneficially Owned by Each Reporting Person

6,440,767

--------------------------------------------------------------------------------

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares

(See Instructions) [X]

--------------------------------------------------------------------------------

13. Percent of Class Represented by Amount in Row (11) 21.8%

--------------------------------------------------------------------------------

14. Type of Reporting Person (See Instructions) IN

--------------------------------------------------------------------------------

Item 1. Security and Issuer

Title of class of securities to which this schedule relates:

Common Stock, $.001 par value per share.

Issuer: Oragenics, Inc.

Address of Issuer: 13700 Progress Boulevard, Alucha, Florida 32615

Item 2. Identity and Background

(a) Name of Reporting Person: George T. Hawes

(b) Residence or business address of Reporting Person: 49 Central Drive,

Plandome, NY 11030

Principal business address of Reporting Person: 49 Central Drive,

Plandome, NY 11030

(d) No.

(e) No.

(f) Citizenship: U.S.A

Item 3. Source and Amount of Funds or Other Consideration

On August 8, 2007, the Reporting Person purchased 1,100,000 shares of common stock and warrants to purchase 1,100,000 shares of common stock from the Issuer, for a total purchase price of $275,000. The warrants are exercisable for a period of one year at an exercise price of $0.58 per share. The purchase was made through the personal funds of the Reporting Person.

Item 4. Purpose of Transaction

The purpose of the acquisition was an investment by the Reporting Person. There are no plans or proposals which the Reporting Person may have which relate to or would result in:

(a) The acquisition by any person of additional securities of the

issuer, or the disposition of securities of the issuer;

(b) An extraordinary corporate transaction, such as a merger,

reorganization or liquidation, involving the issuer or any of its

subsidiaries;

any of its subsidiaries;

(d) Any change in the present board of directors or management of the

issuer, including any plans or proposals to change the number or

term of directors or to fill any existing vacancies on the board,

except as to the Board appointment of the Reporting Person specified

above;

(e) Any material change in the present capitalization or dividend policy

of the issuer;

(f) Any other material change in the issuer's business or corporate

structure including but not limited to, if the issuer is a

registered closed-end investment company, any plans or proposals to

make any changes in its investment policy for which a vote is

required by section 13 of the Investment Company Act of 1940;

(g) Changes in the issuer's charter, bylaws or instruments corresponding

thereto or other actions which may impede the acquisition of control

of the issuer by any person;

(h) Causing a class of securities of the issuer to be delisted from a

national securities exchange or to cease to be authorized to be

quoted in an inter-dealer quotation system of a registered national

securities association;

(i) A class of equity securities of the issuer becoming eligible for

termination of registration pursuant to Section 12(g)(4) of the Act;

(j) Any action similar to any of those enumerated above.

Item 5. Interest in Securities of the Issuer

(a) The aggregate number and percentage of common stock beneficially

owned by the Reporting Person: 6,440,767. The amount includes 1,687,500

and 65,000 shares issuable pursuant to currently exercisable stock warrants and

stock options, respectively. The amount excludes 100,000 shares of common

stock and warrants to purchase 100,000 shares of common stock owned by the

Reporting Person's wife, as to which the Reporting Person disclaims beneficial

ownership. The shares beneficially owned represent approximately 21.8% of the

common stock of the Issuer;

(b) The number of shares as to which there is sole power to vote and

sole power to dispose: 6,440,767;

(d) Not Applicable

(e) Not Applicable

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect

to Securities of the Issuer

Not Applicable

Item 7. Material to Be Filed as Exhibits

Not Applicable

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

August 17, 2007

--------------------------

Date

/s/ George T. Hawes

--------------------------

Signature

George T. Hawes

--------------------------

Name/Title